Pexiganan Dosing & Reconstitution Guide

Pexiganan is administered topically as a cream formulation, specifically designed for application to infected wounds. Clinical studies have indicated that a dose range of 1–2% Pexiganan cream is typically applied twice daily (BID) to the affected area. The dosing frequency is intended to maximize local antimicrobial activity while minimizing systemic exposure. It is important to note that individual responses may vary, and the specific dose should be considered within the context of the research design and objectives. Variability in wound characteristics and patient factors may influence the effectiveness of the treatment, necessitating a conservative approach when determining the appropriate dosing strategy.

In clinical trials, the topical formulation of Pexiganan demonstrated favorable local tolerability, with most participants reporting minimal adverse effects. Common application site reactions, such as erythema and pruritus, were noted in Phase III studies; however, these were generally mild and self-limiting. Importantly, systemic absorption from the topical application is minimal, reducing the risk of systemic side effects. Contraindications for the use of Pexiganan include known hypersensitivity to the peptide or other magainin-derived compounds, as well as deep tissue infections that necessitate systemic antibiotic therapy, as Pexiganan is intended for topical use only. Additionally, insufficient safety data exist regarding its use during pregnancy and breastfeeding, warranting caution in these populations.